Investigating treatment protocols, therapeutic efficacy perceptions, and biosimilar adoption drivers among top medical specialists.
A global biopharmaceutical manufacturer preparing to introduce a novel oncology biologic needed to understand current clinical pathways, treatment barriers, and physician attitudes toward biosimilar alternatives in Morocco's healthcare ecosystem.
MField MEA's dedicated healthcare division engaged and recruited licensed oncologists, hematologists, and hospital pharmacists across University Hospital Centers (CHUs) and private oncology clinics. Double-blind 45-minute interviews were conducted adhering strictly to ESOMAR and pharmacovigilance adverse event reporting guidelines.
Clarified hospital procurement tender mechanics and reimbursement pathway constraints (CNOPS / CNSS / AMO).
Provided foundational clinical evidence that enabled the client to refine their scientific liaison medical education messaging.
Established MField as the preferred medical fieldwork provider for the pharmaceutical client's annual tracking waves.
“Navigating pharmaceutical compliance in North Africa requires immense procedural rigor. MField MEA executed our double-blind protocol with supreme professionalism.”